MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
headlines news headlines   email email to a friend   printer printer friendly   newsletter sign up to newsletter  

Risks And Benefits Of Anti-Thyroid Drugs

Main Category: Endocrinology
Also Included In: Conferences
Article Date: 24 Sep 2009

Kenneth D. Burman, MD, chief of the Endocrine Section at the Washington Hospital Center, Washington, DC and professor in the Department of Medicine at Georgetown University, will outline the risks and benefits of anti-thyroid drugs Sunday September 27 at 9 a.m. when he speaks at the American Thyroid Association's (ATA) 80th Annual Meeting September 23-27, 2009 at The Breakers Hotel in Palm Beach, Florida.

Dr. Burman will examine the mechanisms of action, clinical use and potential adverse effects of anti-thyroid drugs as well as make several recommendations. Anti-thyroid drugs are utilized to treat hyperthyroidism, which frequently occurs due to Graves' disease.

"Methimazole and Propylthiouracil (PTU) are the two most potent anti-thyroid drugs used in the U.S.," explains Dr. Burman. "Their primary effect is to inhibit thyroid hormone synthesis. These agents are effective in lowering thyroid function tests but potential serious adverse effects include low white cell count, liver toxicity and liver failure."

Recent discussion has focused on the liver issues which seem to be more common with PTU as compared to methimazole. Patients receiving PTU should be closely monitored for symptoms and signs of liver injury, especially during the first six months after initiation of therapy.

The FDA has recommended (June 2009) that, in general, PTU should be considered a second-line drug therapy except in patients who are pregnant, allergic to or intolerant of methimazole. During pregnancy, methimazole, but not PTU, has been associated with a rare congenital defect, aplasia cutis, and, therefore, PTU may be more appropriate for patients with Graves' disease who are in their first trimester of pregnancy.

The American Thyroid Association (ATA) is the lead organization in promoting thyroid health and understanding thyroid biology. The ATA values scientific inquiry, clinical excellence, public service, education, collaboration, and collegiality.

A non-profit medical society founded in 1923, the ATA fulfills its mission through supporting excellence and innovation in research, clinical care, education, and public health. ATA members are physicians and scientists who work to enhance the understanding of thyroid physiology and pathophysiology, improve the diagnosis and treatment of thyroid diseases, and promote the education of physicians, patients, and the public about thyroid disorders. The official journal "Thyroid" of the ATA is published monthly. "Clinical Thyroidology" is published online monthly for the benefit of clinicians and scientists around the world.

Thyroid diseases are among the most common disorders of the endocrine system, affecting almost 13 million Americans alone. The ATA has extensive online information for patients on thyroid disease (in English and Spanish) serving the clinician as a resource for patients and the public who look for reliable information on the internet. To further benefit patients, the ATA publishes an online journal "Clinical Thyroidology for Patients." The Alliance for Patient Education was formed in 2002 to offer an exchange of information between the ATA and patient education groups: ThyCa: Thyroid Cancer Survivors' Association, Inc.; the Light of Life Foundation, and the Graves' Disease Foundation. A public forum is held each year in conjunction with the ATA annual meeting.

Source: American Thyroid Association

Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today

Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles.





For any corrections of factual information, or to contact the editors please use our feedback form.
Send your press releases to








free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.